The European Union has granted over 6.5 million euros to the clinical research program PsyPal for investigating psilocybin (the active substance in magic mushrooms) as a psychological treatment for individuals with an incurable, progressive disease.
The UMCG coordinates the research program, which involves 19 organisations across Europe. More than a hundred patients are participating in the study. ‘We are curious to see if we can alleviate the suffering of these patients’, says Robert Schoevers, professor and head of psychiatry at the UMCG. ‘At the same time, we want to investigate the long-term results of this treatment, something that is often overlooked but of tremendous importance.’